Related Experiment Videos
Potential cardiotoxicity with mitoxantrone
Cancer Treatment Reports
|August 1, 1982
Abstract:
Mitoxantrone is a promising new agent developed in an attempt to find drugs with a broad spectrum of antitumor activity and devoid of cardiotoxicity. In a phase II clinical trial for refractory metastatic breast cancer, we observed congestive heart failure in four of 31 high-risk patients either during or after treatment with this drug. This report calls attention to that observation, and recommendation is made that further evaluation of this agent include careful cardiac monitoring.
Insights
Mitoxantrone shows antitumor potential but carries a risk of cardiotoxicity. Further trials require careful cardiac monitoring for patients receiving this chemotherapy agent.
Area of Science:
- Oncology
- Cardiology
- Pharmacology
Background:
- Mitoxantrone was developed as a novel chemotherapy agent with broad-spectrum antitumor activity.
- The drug was designed to minimize cardiotoxicity, a common side effect of anthracyclines.
Observation:
- A Phase II clinical trial investigated mitoxantrone for refractory metastatic breast cancer.
- Congestive heart failure was observed in 4 out of 31 high-risk patients.
Findings:
- The observed cardiotoxicity suggests mitoxantrone may not be devoid of cardiac risks.
- The incidence of congestive heart failure warrants further investigation into mitoxantrone's cardiac safety profile.
Implications:
- Further clinical evaluation of mitoxantrone must include rigorous cardiac monitoring.
- Oncologists should be aware of the potential cardiotoxic effects of mitoxantrone in high-risk patients.